Evoke Pharma — Investor Presentation (March 2015)
29 slides from Evoke Pharma's investor presentation, Mar 11, 2015
Slide 1: Exhibit 99.1
NASDAQ: EVOK Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Confidential This presentation contains forward-looking statements about Evoke Pharma, Inc. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemp
Slide 3: Investment Highlights: EVK-001 Product Candidate
EVK-001 Product Candidate EVK-001: novel intranasal delivery of metoclopramide Symptomatic relief of acute and recurrent diabetic gastroparesis in women Differentiation By-passes dysfunctional stomach for predictable dosing Critical to patients with compromised gastrointestinal motility or experienc
Slide 4: Gastroparesis Overview
Gastroparesis Overview Confidential
Slide 5: Gastroparesis at a Glance
Disorder in which the stomach is delayed in emptying contents to small intestine (in the absence of an obstruction) Interferes with GI absorption of medications and food due to unpredictable gastric emptying and vomiting Characteristic symptom flares of: nausea, vomiting, abdominal pain, early satie
Slide 6: Gastroparesis: Significant Hospital Costs
Since 2006, emergency room visits for gastroparesis increased 44.6%1 Hospitalizations for gastroparesis as primary or secondary diagnosis increased: 138% from 1995-20042 300% 1997-20091 Gastroparesis-related hospitalization costs2 $3.5B in 2004 $20K per patient per admission Gastroparetics utilize3
Slide 7: US Gastroparesis Population is Large and Growing
Potentially 12-16 million patients with symptoms of gastroparesis Increasing prevalence due to growing diabetes rate and disease awareness/recognition Samsom M, Roelofs J. “Prevalence of Delayed Gastric Emptying in Diabetic Patients and Relationship to Dyspeptic Symptoms.” Diabetes Care, Vol. 26, No
Slide 8: Prescribed Medications for Gastroparesis
Motility & Symptoms Metoclopramide (1st line) Domperidone (not approved in the US) Motility Erythromycin (not indicated) Symptoms Odansetron, promethazine PPI’s Narcotics Prescribed Medications for Gastroparesis The Consequences Potential for erratic absorption (significant delay, multi-dose dumping
Slide 9: A novel approach for symptomatic relief of diabetic gastroparesis in women
A novel approach for symptomatic relief for acute and recurrent diabetic gastroparesis in women EVK-001 (Intranasal Metoclopramide) Sites of drug spray and absorption Unlike oral medications, intranasal delivery bypasses the gastrointestinal tract and directly enters the bloodstream Provides predict
Slide 10: Competitive Clinical Development Landscape
Product Class Route Company Development Status EVK-001 Dopamine antagonist & mixed 5-HT3 antagonist/5-HT4 agonist Intranasal Evoke Pharma Phase 3 (enrolling) Phase 2b (n=287) results: Met prespecified symptomatic efficacy endpoint in both doses RM-131 Ghrelin agonist Sub Cutaneous Actavis/Rhythm The
Slide 11: Commercial Opportunity
Commercial Opportunity Confidential
Slide 12: Oral treatments may be less optimal for patients with gastroparesis
Oral treatments may be less optimal for patients with gastroparesis “…in patients who had apparently failed oral metoclopramide trials, yet had no limiting side effect, the subcutaneous route could result in success. This route generates a constant plasma level of the drug when vomiting and unpredic
Slide 13: EVK-001: Compelling Commercial Opportunity
EVK-001: Compelling Commercial Opportunity Confidential Significant Unmet Need Physicians and patients report extensive interest in non-oral treatment alternatives to address unpredictable absorption (via compromised motility or vomiting) Ready-made Market 4 Million prescriptions of oral metoclopram
Slide 14: Metoclopramide: An Established Compound
Source: ZS Associates Gastroparesis quantitative survey (n=121), Questions 3Q30 and 3Q37: What percent of your mild to moderate / moderate to severe gastroparesis patients are being managed with each of the following options? Your percentage can sum to over 100% if patients are receiving more than o
Slide 15: Literature Commentary for Treatment Delivery
Pasricha (2015) “Delayed gastric emptying may also be important in explaining hypoglycemia, and possibly, erratic response to medications in patients with diabetes.” Rao and Camilleri (2010) “Patients with gastroparesis have erratic emptying of solids from the stomach, making plasma drug levels unpr
Slide 16: MDs' Concerns Regarding Absorption Addressed by EVK-001 Profile
Source: ZS Associates Gastroparesis quantitative survey (n=121), Question 4Q5: How much do you agree with each of the following statements? Totals weighted based on average metoclopramide TRx’s per high/medium segment Completely Disagree MDs’ Concerns Regarding Absorption of Medication Are Addressed
Slide 17: Gastroparesis Patients Prefer Nasal Delivery
Source: G&S Research, May 2011 (n = 98). All previously diagnosed with diabetic gastroparesis and enrolled in METO-IN-002. Questions: 31, 35, 37, 38 Gastroparesis Patients Prefer Nasal Delivery Confidential
Slide 18: EVK-001 Payer Reimbursement Landscape Summary
SE = electronic step edit PA = prior authorization QL = quantity limits % of lives represented in sample Commercial Predicted Formulary Access of EVK-001 (n = 10; 104M total US lives represented) Increasing price points Source: ICON / Pricespective, EVK-001Payer Landscape for Gastroparesis July 2012
Slide 19: EVK-001 Intellectual Property Summary
U.S. Granted Patents Patent # U.S. 6,770,262 U.S. 8,334,281 Title Nasal Administration of Agents for the Treatment of Gastroparesis Nasal Formulations of Metoclopramide Expires 2021 2030 PCT Application Application # PCT/US2012/052096 Title Treatment of Symptoms Associated with Female Gastroparesis
Slide 20: Clinical Development
Clinical Development Confidential
Slide 21: Phase 2b Study Design (METO-IN-002)
Phase 2b Study Design (METO-IN-002) US multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging clinical study of EVK-001 in diabetic subjects with gastroparesis 3 treatment arms (placebo, 10 mg and 14 mg) 4-week safety and efficacy study Primary Endpoint Patient Repor
Slide 22: Phase 2b Efficacy Results in Women
Baseline Week 1 Week 2 Week 3 Week 4 p=0.024 p=0.021 Mean mGCSI-DD Total Score Change from Baseline to Week 4 for Females Mean Total Score Change Statistically significant difference between EVK-001 and placebo (p<0.02) for the pre-specified analysis group of females (n=203) Results not significant
Slide 23: Phase 2b Efficacy Results: Gender Disparity in Treatment Effects
Phase 2b Efficacy Results: Gender Disparity in Treatment Effects of EVK-001 vs. Placebo Favors Treatment Favors Placebo = Women = Men No Change *mGCSI-DD = four bolded symptoms. Differences of least-square means of 10 mg treatment scores, 95% confidence intervals Symptom Score Decrease Symptom Score
Slide 24: Favorable Safety Profile
Favorable Safety Profile Majority of AEs were mild/moderate and transient in nature <10% dropouts, includes 5% due to adverse events (AEs) No significant cardiac changes throughout 28‐day treatment period No SAEs reported related to study drug Placebo (N = 95) EVK-001 10 mg IN (N = 95) EVK-001 14 mg
Slide 25: End of Phase 2 FDA Guidance
End of Phase 2 FDA Guidance Required for NDA Filing Not Required for NDA filing Single Phase 3 study in women only (ongoing) Dose, regimen, duration (10 mg, QID, and 28 days), and endpoint Thorough QT study (Completed) Despite absence of cardiac safety issues with metoclopramide Parallel companion s
Slide 26: Phase 3 Study for EVK-001
Phase 3 Study for EVK-001 Similar to successful Phase 2b study in women Double-blind, placebo-controlled, parallel-group, 28 day-study to evaluate the efficacy, safety and population pharmacokinetics in adult female subjects with diabetic gastroparesis Two treatment arms: EVK-001 10 mg or placebo QI
Slide 27: Experienced Senior Management & Board
Experienced Senior Management & Board Cam Garner Chairman, Founder Dave Gonyer, R.Ph. President, CEO, Founder, Director Matt D’Onofrio, MBA Chief Business Officer, Founder Marilyn Carlson, D.M.D, M.D., RAC Chief Medical Officer Confidential
Slide 28: Selected Financial Data
3 Months Ended March 31, 2014 Operating Expense Research & Development $2.2M General Administrative $0.7M Total Operating Expense $2.9M Other (Income) Expense $0.0M Net Loss $2.9M Selected Financial Data Income Statement Data (in US $) March 31, 2014 Cash Balance $14.2M Debt $4.5M Balance Sheet Data
Slide 29: Se 2) > Lu (OS <= a Y <=
Se 2) > Lu (OS <= a Y <= 2